
Glenmark Pharma’s North Carolina facility gets five U.S. FDA observations
The U.S. Food and Drug Administration (FDA) has issued a Form 483 with five observations to Glenmark Pharmaceuticals’ manufacturing facility in Monroe, North Carolina, U.S. The observations were issued at the end of GMP inspection of facility from June 9- …